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Background
Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets 
multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of 
nintedanib twice daily reduced lung-function decline and acute exacerbations in 
patients with idiopathic pulmonary fibrosis.
Methods
We conducted two replicate 52-week, randomized, double-blind, phase 3 trials 
(INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of 
nintedanib twice daily as compared with placebo in patients with idiopathic pul-
monary fibrosis. The primary end point was the annual rate of decline in forced 
vital capacity (FVC). Key secondary end points were the time to the first acute 
exacerbation and the change from baseline in the total score on the St. George’s 
Respiratory Questionnaire, both assessed over a 52-week period.
Results
A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib 
or placebo. The adjusted annual rate of change in FVC was −114.7 ml with nintedanib 
versus −239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 
77.7 to 172.8; P<0.001) in INPULSIS-1 and −113.6 ml with nintedanib versus −207.3 ml 
with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. 
In INPULSIS-1, there was no significant difference between the nintedanib and placebo 
groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 
1.15; 95% CI, 0.54 to 2.42; P = 0.67); in INPULSIS-2, there was a significant benefit 
with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005). 
The most frequent adverse event in the nintedanib groups was diarrhea, with rates 
of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in 
INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.
Conclusions
In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in 
FVC, which is consistent with a slowing of disease progression; nintedanib was fre-
quently associated with diarrhea, which led to discontinuation of the study medica-
tion in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and 
INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.)
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Idiopathic pulmonary fibrosis is a fatal lung disease characterized by worsening dys-pnea and progressive loss of lung function.1 
A decline in forced vital capacity (FVC) is consis-
tent with disease progression and is predictive of 
reduced survival time.1-6
Idiopathic pulmonary fibrosis is believed to 
arise from an aberrant proliferation of fibrous 
tissue and tissue remodeling due to the abnor-
mal function and signaling of alveolar epithelial 
cells and interstitial fibroblasts.7 The activation 
of cell-signaling pathways through tyrosine ki-
nases such as vascular endothelial growth fac-
tor (VEGF), fibroblast growth factor (FGF), and 
platelet-derived growth factor (PDGF) has been 
implicated in the pathogenesis of the disease.8-10
Nintedanib (formerly known as BIBF 1120) is 
an intracellular inhibitor that targets multiple 
tyrosine kinases, including the VEGF, FGF, and 
PDGF receptors.11 The results of an earlier trial 
(To Improve Pulmonary Fibrosis with BIBF 1120 
[TOMORROW]), a randomized, double-blind, 
placebo-controlled, phase 2 dose-finding study 
involving 432 patients with idiopathic pulmonary 
fibrosis, suggested that 12 months of treatment 
with 150 mg of nintedanib twice daily was asso-
ciated with a reduced decline in FVC, fewer acute 
exacerbations, and the preservation of health-
related quality of life.12 We conducted two repli-
cate phase 3 trials (INPULSIS-1 and INPULSIS-2) 
to evaluate the efficacy and safety of treatment 
with 150 mg of nintedanib twice daily in patients 
with idiopathic pulmonary fibrosis.
Me thods
Study Design and Oversight
The INPULSIS studies were randomized, double-
blind, placebo-controlled, parallel-group trials 
performed at 205 sites in 24 countries in the 
Americas, Europe, Asia, and Australia. An inde-
pendent data monitoring committee regularly 
reviewed the data, particularly serious adverse 
events, adverse events leading to discontinuation 
of the study drug, and the results of laboratory 
analyses, and made recommendations concern-
ing the continuation of the trials. An adjudica-
tion committee that was independent of the in-
vestigators and whose members were unaware of 
the group assignments reviewed medical docu-
mentation to adjudicate the primary cause of 
all deaths. The committee also adjudicated all 
adverse events reported by site investigators as 
acute exacerbations, in order to determine wheth-
er the events met the criteria for an acute exacer-
bation of idiopathic pulmonary fibrosis as de-
fined in the protocol, available with the full text 
of this article at NEJM.org. The members of these 
committees are listed in Section B in the Supple-
mentary Appendix, also available at NEJM.org.
Both trials were conducted in accordance with 
the principles of the Declaration of Helsinki and 
the Harmonized Tripartite Guideline for Good 
Clinical Practice from the International Confer-
ence on Harmonization and were approved by 
local authorities. The clinical protocol was ap-
proved by an independent ethics committee or 
institutional review board at each participating 
center. All patients provided written informed 
consent before study entry.
All the authors were involved in the design of 
the study and had access to the data, which were 
analyzed by the study sponsor, Boehringer Ingel-
heim. All the authors vouch for the accuracy and 
completeness of the data analyses and the fidel-
ity of each study to the protocol. The protocol 
and statistical analysis plans are available at 
NEJM.org. The manuscript was drafted by the 
first, second, and last authors and revised by all 
the authors. Medical writing assistance, paid for 
by Boehringer Ingelheim, was provided by the 
Fleishman-Hillard Group.
Patients
Patients were eligible to participate in the two 
trials if they were 40 years of age or older and 
had received a diagnosis of idiopathic pulmonary 
fibrosis within the previous 5 years. Additional 
eligibility criteria were an FVC that was 50% or 
more of the predicted value, a diffusion capacity 
of the lung for carbon monoxide (DLCO) that was 
30 to 79% of the predicted value, and high-reso-
lution computed tomography (HRCT) of the chest 
performed within the previous 12 months. HRCT 
images (for all patients) and lung-biopsy speci-
mens (if available) were reviewed centrally by a 
single radiologist and a single pathologist to verify 
eligibility according to the protocol. Eligi bility cri-
teria with regard to findings on HRCT and surgi-
cal lung biopsy are shown in Table S1 and Table S2, 
respectively, in the Supplementary Appendix.
Concomitant therapy with up to 15 mg of 
prednisone per day, or the equivalent, was per-
mitted if the dose had been stable for 8 or more 
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weeks before screening; patients receiving other 
therapies for idiopathic pulmonary fibrosis, 
including high-dose prednisone, azathioprine, 
N-acetylcysteine, and any investigational treat-
ments for idiopathic pulmonary fibrosis, were 
excluded. After 6 months of study treatment, 
patients whose condition had deteriorated could 
receive azathioprine, cyclophosphamide, cyclo-
sporine, N-acetylcysteine, or more than 15 mg of 
prednisone per day, or the equivalent, at the dis-
cretion of the investigator. In cases of acute exac-
erbation reported by an investigator at any time 
during the trial, any treatments could be initiated 
or doses increased as deemed appropriate by the 
investigator. Other key exclusion criteria are listed 
in Section C in the Supplementary Appendix.
Study Protocol
After a screening period, eligible patients were 
randomly assigned in a 3:2 ratio to receive 150 mg 
of nintedanib twice daily or placebo for 52 weeks. 
An interactive telephone and Web-based response 
system was used to perform randomization. 
Patients, investigators, and the study sponsor 
were unaware of the study-group assignments 
throughout the study. Completion of the 52-week 
treatment period was followed by a follow-up visit 
4 weeks later. Spirometric tests were conducted 
at baseline; at 2, 4, 6, 12, 24, 36, and 52 weeks; 
and at the follow-up visit. Spirometric testing 
was conducted in accordance with criteria pub-
lished by the American Thoracic Society and the 
European Respiratory Society.13 All spirometric 
measurements were performed on machines pro-
vided by the sponsor, and the results were cen-
trally reviewed, with training and ongoing feed-
back provided for the site investigators.
Dose interruption or reduction of the dose 
from 150 mg twice daily to 100 mg twice daily 
was allowed for the management of adverse 
events. After an adverse event had resolved, the 
dose could be reinstituted at 150 mg twice daily. 
The site investigators were provided with recom-
mendations for the management of diarrhea and 
elevated levels of liver enzymes. To minimize the 
amount of missing data, patients who discontin-
ued the study drug prematurely were asked to 
attend all scheduled visits and to undergo all 
examinations as originally planned. For patients 
who discontinued the drug prematurely but did 
not agree to attend all visits, data on vital status 
were collected at week 52.
End Points
The primary end point for both INPULSIS trials 
was the annual rate of decline in FVC (measured 
in milliliters per year). Key secondary end points 
were the time to the first acute exacerbation (as 
reported by a site investigator) and the change 
from baseline in the total score on the St. 
George’s Respiratory Questionnaire (SGRQ), both 
assessed over the 52-week treatment period. The 
SGRQ is a self-administered questionnaire that 
is used to assess health-related quality of life. It 
comprises three domains (symptoms, activity, 
and impact). The total score and the score for 
each domain range from 0 to 100, with higher 
scores indicating worse health-related quality of 
life.14,15 A minimally important difference in the 
score has not been established for patients with 
idiopathic pulmonary fibrosis; in patients with 
chronic obstructive pulmonary disease, this dif-
ference is 4 points.16 Patients completed the SGRQ 
at baseline and at 6, 12, 24, and 52 weeks. Acute 
exacerbations were defined as events meeting all 
of the following criteria: unexplained worsening 
or development of dyspnea within the previous 
30 days; new diffuse pulmonary infiltrates visu-
alized on chest radiography, HRCT, or both, or 
the development of parenchymal abnormalities 
with no pneumothorax or pleural effusion (new 
ground-glass opacities) since the preceding visit; 
and exclusion of any known causes of acute wors-
ening, including infection, left heart failure, pul-
monary embolism, and any identifiable cause of 
acute lung injury, in accordance with routine clin-
ical practice and microbiologic studies. All acute 
exacerbations reported by the site investigators 
were categorized by the adjudication committee, 
whose members were unaware of the study-group 
assignments, as confirmed or suspected or were 
not considered to be an acute exacerbation accord-
ing to prespecified criteria.17
Other prespecified secondary end points in-
cluded the absolute change from baseline in FVC 
(in milliliters and as a percentage of the pre-
dicted value) over the 52-week treatment period, 
the proportion of patients with an FVC response 
(defined as the proportion of patients in whom 
the percentage of predicted FVC did not decline 
by more than 5 percentage points or by more 
than 10 percentage points at week 52), the risk 
of an acute exacerbation, the change from base-
line in SGRQ domain scores over the 52-week 
treatment period, death from any cause, death 
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from a respiratory cause, and death that oc-
curred between randomization and 28 days after 
the last dose of the study drug. All mortality end 
points were measured as the time to death. 
Safety was assessed by means of clinical and 
laboratory evaluation at study visits and the re-
cording of adverse events.
Statistical Analysis
Efficacy and safety analyses were conducted for pa-
tients who were randomly assigned to a study group 
and received at least one dose of the study medi-
cation. The primary end point was analyzed with 
the use of a random coefficient regression model 
(with random slopes and intercepts) that includ-
ed sex, age, and height as covariates. The treat-
ment effect was determined by using estimated 
slopes for each study group (on the basis of the 
time-by-treatment interaction term from the 
mixed model). All available FVC values from base-
line to week 52 were used in the primary model, 
including FVC measurements at the follow-up 
visit for patients who discontinued the study 
medication prematurely and did not complete the 
study visits through week 52. The statistical 
model used for the primary analysis allowed for 
missing data, assuming that they were missing 
at random; missing data were not imputed for 
the primary analysis, but data collected after dis-
continuation of the study drug were used in the 
primary analysis. Significance tests were two-
sided, with an alpha value of 0.05.
The superiority of nintedanib over placebo 
with respect to the primary and key secondary 
end points was tested with the use of a hierar-
chical procedure to account for multiple com-
parisons (see Section D in the Supplementary 
Appendix). Sensitivity analyses were performed 
to assess the robustness of the results for the 
primary and key secondary end points. Multiple 
imputation sensitivity analyses were performed 
to assess the effect of missing data and provide 
estimates of the treatment effect under different 
assumptions about missing data (Fig. S2 in the 
Supplementary Appendix). For the time to the 
first acute exacerbation, a sensitivity analysis 
based on the occurrence of confirmed or sus-
pected acute exacerbations (as determined by the 
adjudication committee) in pooled data from the 
two trials was prespecified.
The frequency and severity of adverse events 
were documented according to the Medical Dic tion­
ary for Regulatory Activities, version 16.1. Safety 
analyses were descriptive. For information on 
the statistical analysis of other end points, see 
Section D in the Supplementary Appendix.
For each trial, the sample size was calculated 
to provide 90% power to detect a between-group 
difference of 100 ml in the annual rate of FVC 
decline. On the basis of data from the phase 2 
trial, the standard deviation for the change in 
FVC from baseline was assumed to be 300 ml in 
both groups. Assuming that it would not be pos-
sible to evaluate data for 2% of patients, the 
sample size was calculated as 194 patients in the 
placebo group and 291 patients in the ninteda-
nib group for a two-group t-test at a one-sided 
significance level of 2.5%. Since the primary 
analysis was based on a random coefficient re-
gression model that included adjustment for sev-
eral variables and took into account information 
across time, we expected that the power would 
be greater than the 90% calculated for the t-test.
R esult s
Patients
Between May 2011 and September 2012, a total 
of 1066 patients underwent randomization: 
515 patients in INPULSIS-1 and 551 patients in 
INPULSIS-2 (Fig. S1 in the Supplementary Ap-
pen dix). In INPULSIS-1, a total of 513 patients 
received at least one dose of the study medica-
tion (309 received nintedanib and 204 received 
placebo). A total of 78 patients (25.2%) in the 
nintedanib group and 36 patients (17.6%) in the 
placebo group discontinued the study medica-
tion prematurely. Of these patients, 31 (39.7%) 
in the nintedanib group and 11 (30.6%) in the 
placebo group completed visits up to week 52. 
The most frequent reason for premature discon-
tinuation of the study medication was at least 
one adverse event (65 patients [21.0%] in the 
nintedanib group and 24 [11.8%] in the placebo 
group). In INPULSIS-2, a total of 548 patients 
received at least one dose of the study medica-
tion (329 received nintedanib and 219 received 
placebo). A total of 78 patients (23.7%) in the nin-
tedanib group and 44 patients (20.1%) in the pla-
cebo group discontinued the study medication 
prematurely. Of these patients, 26 (33.3%) in 
the nin ted anib group and 10 (22.7%) in the pla-
cebo group completed visits up to week 52. The 
most frequent reason for premature discontinu-
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ation of the study medication was at least one 
adverse event (62 patients [18.8%] in the nin-
tedanib group and 35 [16.0%] in the placebo 
group). The proportion of patients with missing 
FVC data at week 52 was approximately 15%; 
the proportion of patients with missing data did 
not differ significantly between the nintedanib 
and placebo groups (Fig. S2 in the Supplementary 
Appendix).
In each trial, the baseline characteristics of 
patients in the nintedanib and placebo groups 
were similar (Table 1, and Table S3 in the Sup-
plementary Appendix). The mean duration of 
exposure to the study drug in the nintedanib 
and placebo groups was similar (approximately 
45 weeks in each trial), but a higher proportion 
of patients in the nintedanib group than in the 
placebo group had dose reductions or interrup-
Table 1. Baseline Characteristics of Patients in INPULSIS-1 and INPULSIS-2.*
Characteristic INPULSIS-1 INPULSIS-2
Nintedanib  
(N = 309)
Placebo  
(N = 204)
Nintedanib  
 (N = 329)
Placebo  
(N = 219)
Male sex — no. (%) 251 (81.2) 163 (79.9) 256 (77.8) 171 (78.1)
Age — yr 66.9±8.4 66.9±8.2 66.4±7.9 67.1±7.5
Weight — kg 82.0±16.8 81.2±16.3 76.6±15.9 76.3±16.5
Body-mass index† 28.6±4.5 28.1±4.6 27.6±4.6 27.2±4.5
Smoking status — no. (%)
Never smoked 71 (23.0) 51 (25.0) 103 (31.3) 71 (32.4)
Former smoker 217 (70.2) 144 (70.6) 218 (66.3) 139 (63.5)
Current smoker 21 (6.8) 9 (4.4) 8 (2.4) 9 (4.1)
Time since diagnosis of idiopathic pulmonary fibrosis 
— yr
1.7±1.4 1.6±1.4 1.6±1.3 1.6±1.3
Specimen from surgical lung biopsy available  
— no. (%)
60 (19.4) 33 (16.2) 84 (25.5) 52 (23.7)
Systemic corticosteroid therapy — no. (%)‡ 68 (22.0) 43 (21.1) 68 (20.7) 46 (21.0)
FVC
Mean — ml 2757±735 2845±820 2673±776 2619±787
Median — ml 2700 2721 2615 2591
Percentage of predicted value 79.5±17.0 80.5±17.3 80.0±18.1 78.1±19.0
FEV1:FVC (%) 81.5±5.4 80.8±6.1 81.8±6.3 82.4±5.7
DLco
mmol/min/kPa 4.0±1.2 4.0±1.1 3.8±1.2 3.7±1.3
Percentage of predicted value§ 47.8±12.3 47.5±11.7 47.0±14.5 46.4±14.8
Spo2 — % 95.9±2.0 95.9±1.9 95.8±2.6 95.7±2.1
Total SGRQ score¶ 39.6±17.6 39.8±18.5 39.5±20.5 39.4±18.7
* Plus–minus values are means ±SD. FEV1 denotes forced expiratory volume in 1 second, FVC forced vital capacity, and 
Spo2 oxygen saturation of peripheral blood.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ Prednisone at a dose of no more than 15 mg per day or the equivalent was permitted if the dose had been stable for at 
least 8 weeks before screening.
§ The percentage of the predicted value for the diffusion capacity of the lung for carbon monoxide (DLco) was calculated 
with the use of the equation described by the European Community for Steel and Coal in Cotes et al.18 In INPULSIS-2, 
data were available for 218 patients in the placebo group.
¶ In INPULSIS-1, the total score on the St. George’s Respiratory Questionnaire (SGRQ) was available for 298 patients  
in the nintedanib group and 202 patients in the placebo group; in INPULSIS-2, the total SGRQ score was available for 
326 patients in the nintedanib group and 217 patients in the placebo group. The total score ranges from 0 to 100, with 
higher scores indicating worse health-related quality of life.
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tions (Table S4 in the Supplementary Appendix). 
The dose intensity — the amount of drug admin-
istered divided by the amount that would have 
been administered had the regimen of 150 mg 
twice daily been followed throughout the study 
or until permanent discontinuation of the study 
medication — was more than 90% in 75.9% of 
patients in the nintedanib groups.
Lung Function
In both trials, the adjusted annual rate of change 
in FVC was significantly lower in the nintedanib 
group than in the placebo group. In INPULSIS-1, 
the rate was −114.7 ml per year in the nintedanib 
group as compared with −239.9 ml per year in 
the placebo group, representing a difference of 
125.3 ml per year (95% confidence interval [CI], 
77.7 to 172.8; P<0.001) (Fig. 1A). In INPULSIS-2, 
the rate was −113.6 ml per year in the nintedanib 
group as compared with −207.3 ml per year in 
the placebo group, representing a difference of 
93.7 ml per year (95% CI, 44.8 to 142.7; P<0.001) 
(Fig. 1C). In both trials, the results of prespeci-
fied sensitivity analyses were consistent with 
the results of the primary analysis (Fig. S2 in the 
Supplementary Appendix). In particular, in the 
multiple imputation analyses, which were based 
on the conservative assumption that missing data 
were informative rather than random, the esti-
mates of treatment effect and the corresponding 
confidence intervals were consistent with the re-
sults of the primary analysis in each study. This 
finding shows that the primary results are robust 
and were not influenced by alternative assump-
tions about missing data. In addition, the mean 
observed changes in FVC over time (unadjusted, 
nonimputed results) were consistent with the re-
sults of the primary analysis in both trials (Fig. 
1B and 1D).
In each trial, a significantly greater propor-
tion of patients in the nintedanib group than in 
the placebo group had a response in FVC when 
patients with a response were defined as those 
who did not have an absolute decline in the per-
centage of predicted FVC that was more than 
5 percentage points at week 52 (Table 2). When 
patients with a response in FVC were defined as 
those who did not have an absolute decline in the 
percentage of predicted FVC that was more than 
10 percentage points at week 52, a significantly 
greater proportion of patients in the nintedanib 
group than in the placebo group had a response T
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in INPULSIS-1; in INPULSIS-2, the difference 
between the groups was not significant.
A prespecified pooled analysis of the primary 
end point showed a significant treatment effect, 
(between-group difference in the annual rate of 
FVC change, 109.9 ml  [95% CI, 75.9 to 144.0]) 
(Fig. S3A in the Supplementary Ap pendix). 
Pooled data on the absolute change from base-
line in FVC are shown in Table S5 and Figure 
S3B in the Supplementary Appendix. A pre-
specified pooled analysis of data from the two 
trials showed that a significantly greater propor-
tion of patients in the nintedanib group than in 
the placebo group had an FVC response with 
both definitions of a response (a decline in the 
percentage of predicted FVC that was not more 
than 5 percentage points and a decline that was 
not more than 10 percentage points at week 52) 
(Table S5 in the Supplementary Appendix).
Acute Exacerbations
In INPULSIS-1, there was no significant differ-
ence between the nintedanib and placebo groups 
in the time to the first acute exacerbation (haz-
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Figure 2. Time to First Investigator-Reported Acute Exacerbation in INPULSIS-1 and INPULSIS-2.
The New England Journal of Medicine 
Downloaded from nejm.org on February 3, 2017. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
Nintedanib in Idiopathic Pulmonary Fibrosis
n engl j med 370;22 nejm.org may 29, 2014 2079
ard ratio in the nintedanib group, 1.15; 95% CI, 
0.54 to 2.42; P = 0.67) (Fig. 2A), and the propor-
tion of patients with at least one investigator-
reported acute exacerbation was similar in the 
nintedanib and placebo groups (6.1% and 5.4%, 
respectively). In INPULSIS-2, there was a signifi-
cant increase in the time to the first acute exac-
erbation in the nintedanib group as compared 
with the placebo group (hazard ratio, 0.38; 95% 
CI, 0.19 to 0.77; P = 0.005) (Fig. 2B), and the pro-
portion of patients with at least one investigator-
reported acute exacerbation was lower in the 
nintedanib group than in the placebo group 
(3.6% vs. 9.6%). In the prespecified pooled analy-
sis, there was no significant difference between 
the nintedanib and placebo groups in time to first 
investigator-reported acute exacerbation (hazard 
ratio, 0.64; 95% CI, 0.39 to 1.05; P = 0.08); the 
proportion of patients with at least one investiga-
tor-reported acute exacerbation was 4.9% in the 
nintedanib group and 7.6% in the placebo group 
(Fig. S4 and S5 in the Supplementary Appendix). 
A prespecified sensitivity analysis of pooled data 
on the time to the first adjudicated acute exacer-
bation (confirmed or suspected) showed that 
nintedanib had a significant benefit as com-
pared with placebo (Table S6 and Fig. S6 in the 
Supplementary Appendix).
SGRQ Score
In INPULSIS-1, there was no significant between-
group difference in the adjusted mean change in 
the total SGRQ score from baseline to week 52 
(4.34 points in the nintedanib group and 4.39 
points in the placebo group; difference, −0.05; 
95% CI, −2.50 to 2.40; P = 0.97); in INPULSIS-2, 
there was a significantly smaller increase in the 
total SGRQ score at week 52 (consistent with less 
deterioration in health-related quality of life) in 
the nintedanib group than in the placebo group 
(2.80 points vs. 5.48 points; difference, −2.69; 
95% CI, −4.95 to −0.43; P = 0.02) (Fig. S7A and S7B 
in the Supplementary Appendix).
In the prespecified pooled analysis of the to-
tal SGRQ score, there was no significant differ-
ence in the adjusted mean change from baseline 
to week 52 between the nintedanib and placebo 
groups (difference, −1.43 points; 95% CI, −3.09 
to 0.23; P = 0.09) (Fig. S7C in the Supplementary 
Appendix). Changes from baseline in SGRQ do-
main scores were consistent with the changes in 
the total SGRQ score in each trial (Tables S7A 
and S7B in the Supplementary Appendix) and in 
the pooled analysis (Table S7C in the Supple-
mentary Appendix).
Deaths
In the prespecified pooled analysis, there was no 
significant between-group difference in death 
from any cause, death from a respiratory cause, 
or death that occurred between randomization 
and 28 days after the last dose of the study drug 
(Table S8 in the Supplementary Appendix). The 
proportion of patients who died from any cause 
over the 52-week treatment period was 5.5% in 
the nintedanib group and 7.8% in the placebo 
group (hazard ratio in the nintedanib group, 
0.70; 95% CI, 0.43 to 1.12; P = 0.14) (Fig. S8 in the 
Supplementary Appendix).
Adverse Events
The most frequent adverse event in the ninteda-
nib groups in both trials was diarrhea (Table 3). 
Among the patients in the nintedanib groups 
who had diarrhea, most reported events that 
were of mild or moderate intensity (93.7% in 
INPULSIS-1 and 95.2% in INPULSIS-2). Diarrhea 
led to premature discontinuation of the study 
drug in 14 patients receiving nintedanib (4.5%) 
and none of the patients receiving placebo in 
INPULSIS-1 and in 14 patients receiving ninteda-
nib (4.3%) and 1 receiving placebo (0.5%) in 
INPULSIS-2.
In both trials, the proportion of patients with 
serious adverse events was similar in the ninteda-
nib and placebo groups (Table 3). In INPULSIS-1, 
serious adverse events were reported in 31.1% of 
patients in the nintedanib group and in 27.0% 
of patients in the placebo group; in INPULSIS-2, 
the percentages were 29.8% and 32.9%, respec-
tively.
In both trials, a higher proportion of patients in 
the nintedanib groups than in the placebo groups 
had elevated levels of liver enzymes (Table S9 in 
the Supplementary Appendix). In INPULSIS-1, a 
total of 15 patients in the nintedanib group 
(4.9%) and 1 patient in the placebo group (0.5%) 
had levels of aspartate aminotransferase, alanine 
aminotransferase, or both that were three or 
more times the upper limit of the normal range. 
In INPULSIS-2, a total of 17 patients in the nin-
tedanib group (5.2%) and 2 patients in the pla-
cebo group (0.9%) had such elevations.
Among the infrequent events (those occurring 
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in less than 2% of a study group) that were of 
potential clinical importance, myocardial infarc-
tion was reported in 5 patients in the ninteda nib 
group (1.6%) and 1 patient in the placebo group 
(0.5%) in INPULSIS-1, and in 5 patients in the 
nintedanib group (1.5%) and 1 patient in the 
placebo group (0.5%) in INPULSIS-2. In total, two 
events in the nintedanib groups and one event in 
Table 3. Adverse Events.
Event INPULSIS-1 INPULSIS-2
Nintedanib 
(N = 309)
Placebo  
(N = 204)
Nintedanib 
(N = 329)
Placebo  
(N = 219)
number of patients (percent)
Any adverse event 298 (96.4) 181 (88.7) 311 (94.5) 198 (90.4)
Any adverse event, excluding progression 
of idiopathic pulmonary fibrosis*
296 (95.8) 179 (87.7) 311 (94.5) 197 (90.0)
Most frequent adverse events†
Diarrhea 190 (61.5) 38 (18.6) 208 (63.2) 40 (18.3)
Nausea 70 (22.7) 12 (5.9) 86 (26.1) 16 (7.3)
Nasopharyngitis 39 (12.6) 34 (16.7) 48 (14.6) 34 (15.5)
Cough 47 (15.2) 26 (12.7) 38 (11.6) 31 (14.2)
Progression of idiopathic pulmonary fibrosis* 31 (10.0) 21 (10.3) 33 (10.0) 40 (18.3)
Bronchitis 36 (11.7) 28 (13.7) 31 (9.4) 17 (7.8)
Upper respiratory tract infection 28 (9.1) 18 (8.8) 30 (9.1) 24 (11.0)
Dyspnea 22 (7.1) 23 (11.3) 27 (8.2) 25 (11.4)
Decreased appetite 26 (8.4) 14 (6.9) 42 (12.8) 10 (4.6)
Vomiting 40 (12.9) 4 (2.0) 34 (10.3) 7 (3.2)
Weight loss 25 (8.1) 13 (6.4) 37 (11.2) 2 (0.9)
Severe adverse events‡ 81 (26.2) 37 (18.1) 93 (28.3) 62 (28.3)
Serious adverse events‡ 96 (31.1) 55 (27.0) 98 (29.8) 72 (32.9)
Fatal adverse events 12 (3.9) 10 (4.9) 25 (7.6) 21 (9.6)
Adverse events leading to treatment 
discontinuation§
65 (21.0) 22 (10.8) 58 (17.6) 33 (15.1)
Gastrointestinal disorders 26 (8.4) 3 (1.5) 21 (6.4) 2 (0.9)
Respiratory, thoracic, and mediastinal 
disorders
12 (3.9) 10 (4.9) 8 (2.4) 18 (8.2)
Investigation results¶ 10 (3.2) 1 (0.5) 8 (2.4) 1 (0.5)
Cardiac disorders 5 (1.6) 4 (2.0) 2 (0.6) 3 (1.4)
General disorders and conditions involving 
site of study-drug administration‖
8 (2.6) 3 (1.5) 2 (0.6) 1 (0.5)
* Progression of idiopathic pulmonary fibrosis was defined in accordance with the definition of idiopathic pulmonary fi-
brosis in the Medical Dictionary for Regulatory Activities, version 16.1, which includes disease worsening and exacerba-
tions of idiopathic pulmonary fibrosis.
† The most frequent adverse events were defined as those with an incidence of more than 10% in any study group.
‡ A severe adverse event was related to intensity and was defined as an event that was incapacitating or that caused an in-
ability to work or to perform usual activities. A serious adverse event was defined as any adverse event that resulted in death, 
was immediately life-threatening, resulted in persistent or clinically significant disability or incapacity, required or pro-
longed hospitalization, was related to a congenital anomaly or birth defect, or was deemed serious for any other reason.
§ Adverse events leading to study-drug discontinuation were reported when they occurred in 2% or more of patients in 
any study group and are listed according to system organ class. The analysis included adverse events with an onset 
 after administration of the first dose of study medication and up to 28 days after administration of the last dose.
¶ Investigation results refer to the results of clinical laboratory tests, radiologic tests, physical examination, and physio-
logic tests.
‖ These events include disorders or conditions that involve several body systems or sites, including chest pain, fatigue, 
asthenia, and general deterioration of physical health.
The New England Journal of Medicine 
Downloaded from nejm.org on February 3, 2017. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
Nintedanib in Idiopathic Pulmonary Fibrosis
n engl j med 370;22 nejm.org may 29, 2014 2081
the placebo groups were fatal. Occur rences of 
adverse events related to cardiac disorders, in-
cluding ischemic heart disease, are summarized 
in Table S10 in the Supplementary Appendix.
Discussion
In both the INPULSIS trials, nintedanib signifi-
cantly reduced the rate of decline in FVC over the 
52-week treatment period. The robustness of this 
finding was supported by the results of all pre-
specified sensitivity analyses, including those 
assessing alternative ways of handling missing 
data. The treatment effect for the annual rate of 
decline in FVC was consistent with the treatment 
effect for the absolute change from baseline in 
FVC. The curves for changes from baseline in 
FVC over time in the nintedanib and placebo 
groups separated early in the two studies and 
continued to diverge over time.
A smaller proportion of patients in the ninteda-
nib groups than in the placebo groups had an 
absolute decline in the percentage of predicted 
FVC of more than 5 percentage points, an obser-
vation that supports the clinical relevance of the 
results. No consistent effect of nintedanib on 
the time to the first acute exacerbation or on the 
change in the total SGRQ score was observed in 
the two trials. This difference in the key second-
ary end point results between INPULSIS-1 and 
INPULSIS-2 was not explained by the differences 
in baseline characteristics between the trials.
Acute exacerbations of idiopathic pulmonary 
fibrosis are events of major clinical significance 
that are associated with high morbidity and 
mortality.17,19 The INPULSIS trials showed that 
the effect of nintedanib was inconsistent with 
respect to the risk of investigator-reported acute 
exacerbations. Exacerbations are relatively rare 
events in patients with idiopathic pulmonary fi-
brosis who are in clinical trials and are difficult 
to assess and categorize, which may explain 
some of the heterogeneity in our findings.20
In both trials, the most frequent adverse 
events in the nintedanib groups were gastrointes-
tinal in nature, with the majority of patients who 
received nintedanib reporting diarrhea. However, 
the proportion of patients in the nintedanib 
groups with diarrhea that led to premature dis-
continuation of the study medication was less than 
5% (4.5% in INPULSIS-1 and 4.3% in INPULSIS-2). 
In both trials, the mean dose intensity in the 
nintedanib groups was greater than 90%. These 
results show that although adverse events asso-
ciated with nintedanib treatment were not infre-
quent, the dosing regimen used in the INPULSIS 
trials was successful in minimizing treatment 
discontinuations. Although serious adverse events 
reflecting ischemic heart disease were balanced 
between the nintedanib and placebo groups, a 
higher percentage of patients in the nintedanib 
groups had myocardial infarctions. The clinical 
significance of this finding is unknown, and 
further observation in larger cohorts is needed.
In conclusion, data from the INPULSIS trials 
show that in patients with idiopathic pulmonary 
fibrosis, nintedanib reduced the decline in FVC, 
which is consistent with a slowing of disease 
progression. There were significant differences 
in favor of nintedanib for the time to the first 
acute exacerbation and the change from baseline 
in the total SGRQ score in INPULSIS-2 but not 
in INPULSIS-1. Adverse events were common in 
the nintedanib groups in both trials; nonethe-
less, most patients continued to receive ninted-
anib for the duration of the treatment period.
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